Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Roxadustat
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recent endorsement of Evrenzo (roxadustat) by the National Institute for Health and Care Excellence (NICE) could be a catalyst for further use as alternative to erythropoietin stimulating agents (ESAs).
Product Name : Evrenzo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2022
Lead Product(s) : Roxadustat
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
